Hydrogen sulfide inhibits abnormal proliferation of lymphocytes via AKT/GSK3β Signal pathway in systemic lupus erythematosus patients

Cellular Physiology and Biochemistry

Volumn 31, Issue 6, 2013, Pages 795-804

  Han, Yanfang ^a   Zeng, Fanqin ^a   Tan, Guozhen ^a   Yang, Chuntao ^b   Tang, Hongfeng ^c   Luo, Yijin ^a   Feng, Jianqiang ^d   Xiong, Hui ^a   Guo, Qing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b 2nd Affiliated Hospital   (China)

^c SHUNDE HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

AKT; Cell cycle; GSK3 ; Hydrogen sulfide; Lymphocytes; Systemic lupus erythematosus

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROGEN SULFIDE; LITHIUM CHLORIDE; PHYTOHEMAGGLUTININ; PROTEIN KINASE B; SODIUM; GYY 4137; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVATION; CELL COUNT; CELL CYCLE; CELL CYCLE S PHASE; CELL ISOLATION; CELL STIMULATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR; ENZYME PHOSPHORYLATION; EXPOSURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KIDNEY DISEASE; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; WESTERN BLOTTING; ANTIPROLIFERATIVE ACTIVITY; CONCENTRATION (PARAMETERS); DRUG ANTAGONISM; DRUG MECHANISM; LUPUS ERYTHEMATOSUS NEPHRITIS; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION;

EID: 84878366916     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000350097     Document Type: Article

References (24)

1. Crispin JC, Liossis S-NC, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang Y-T, Tsokos GC: Pathogenesis of human systemic lupus erythematosus: Recent advances. Trends Mol Med 2010;16:47-57.
2. King PD: Lupus-like autoimmunity caused by defects int-cell signal transduction. Curr Opin Investig Drugs 2004;5:517-523.
3. So L, Fruman DA: Pi3k signalling in b- and t-lymphocytes: New developments and therapeutic advances. Biochem J 2012;442:465-481.
4. Zhu J, Liu X, Xie C, Yan M, Yu Y, Sobel ES, Wakeland EK, Mohan C: T cell hyperactivity in lupus as a consequence of hyperstimulatory antigen-presenting cells. J Clin Invest 2005;115:1869-1878. (Pubitemid 40979726)
5. Wu X Mohan C: The akt axis as a therapeutic target in autoimmune diseases. Endocr Metab Immune Disord Drug Targets 2009;9:145-150.
6. Tang H, Tan G, Guo Q, Pang R, Zeng F: Abnormal activation of the akt-gsk3ß signaling pathway in peripheral blood t cells from patients with systemic lupus erythematosus. Cell Cycle 2009;8:2789-2793.
7. Baskar R, Bian J: Hydrogen sulfide gas has cell growth regulatory role. Eur J Pharmacol 2011;656:5-9.
8. Baskar R, Sparatore A, Del Soldato P, Moore PK: Effect of s-diclofenac, a novel hydrogen sulfide releasing derivative inhibit rat vascular smooth muscle cell proliferation. Eur J Pharmacol 2008;594:1-8.
9. Suzuki K, Olah G, Modis K, Coletta C, Kulp G, Gero D, Szoleczky P, Chang T, Zhou Z, Wu L, Wang R Papapetropoulos A, Szabo C: Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function. Proc Natl Acad Sei 2011;108:13829-13834.
10. Yang C, Yang Z, Zhang M, Dong Q, Wang X, Lan A, Zeng F, Chen P, Wang C, Feng J: Hydrogen sulfide protects against chemical hypoxia-induced cytotoxicity and inflammation in hacat cells through inhibition of ros/ nf-kappab/cox-2 pathway. PLoS ONE 2011;6:e21971.
11. Mirandola P, Gobb G, Sponzilli I, Pambianco M, Malinverno C, Cacchioli A, Panfilis Gd, Vitale M: Exogenous hydrogen sulfide induces functional inhibition and cell death of cytotoxic lymphocytes subsets. J Cell Physiol 2007;213:826-833. (Pubitemid 350058277)
12. Miller TW, Wang EA, Gould S, Stein EV, Kaur S, Lim L, Amarnath S, Fowler DH, Roberts DD: Hydrogen sulfide is an endogenous potentiator of t cell activation. J Biol Chem 2012;287:4211-4221.
13. Zhou K, Gao Q, Zheng S, Pan S, Li P, Suo K, Simoncini T, Wang T, Fu X: 17beta-estradiol induces vasorelaxation by stimulating endothelial hydrogen sulfide release. Mol Hum Reprod 2013;19:169-176.
14. Hughes MN, Centelles MN, Moore KP: Making and working with hydrogen sulfide: The chemistry and generation of hydrogen sulfide in vitro and its measurement in vivo: A review. Free Radie Biol Med 2009;47:1346-1353.
15. Li L, Rose P, Moore PK: Hydrogen sulfide and cell signaling. Annu Rev Pharmacol Toxicol 2011;51:169-187.
16. Deplancke B, Gaskins HR: Hydrogen sulfide induces serum-independent cell cycle entry in nontransformed rat intestinal epithelial cells. FASEB J 2003;17:1310-1312.
17. Rinaldi L, Gobbi G, Pamb ianco M, Micheloni C, Mirandola P, Vitale M: Hydrogen sulfide prevents apoptosis of human pmn via inhibition of p38 and caspase 3. Lab Invest 2006;86:391-397.
18. +/- mice. Science 1999;285:2122-2125. (Pubitemid 29451429)
19. Szabo C: Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 2007;6:917-935. (Pubitemid 350042399)
20. Ewelina Lowicka, Bettowski J: Hydrogen sulfide (h2s) - the third gas of interest for pharmacologists. Pharmacol Rep 2007;59:4-24. (Pubitemid 46522698)
21. Olson KR: The therapeutic potential of hydrogen sulfide: Separating hype from hope. Am J Physiol Regul Integr Comp Physiol 2011;301:17.
22. Chattopadhyay M, Kodela R, Nath N, Dastagirzada YM, Velazquez-Martinez CA, Boring D, Kashfi K: Hydrogen sulfide-releasing nsaids inhibit the growth of human cancer cells: A general property and evidence of a tissue type-independent effect. Biochem Pharmacol 2012;83:715-722.
23. Wallace JL, Caliendo G, Santagada V Cirino G, Fiorucci S: Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 2007; 132:261-271. (Pubitemid 46108763)
24. Zavaczki E, Jeney V, Agarwal A, Zarjou A, Oros M, Katko M, Varga Z, Balla G, Balla J: Hydrogen sulfide inhibits the calcification and osteoblastic differentiation of vascular smooth muscle cells. Kidney Int 2011;80:731-739.